58. (Amended) A pharmaceutical aerosol formulation as claimed in claim 57, wherein the formulation comprises a density-matched propellant mixture of 1,1,1,2-tetrafluoroethane (P134a) and 1,1,1,2,3,3,3-heptafluoropropane (P227).

59. (Amended) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the medicament is selected from the group consisting of a β2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid.

60. (Amended) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the medicament is selected from the group consisting of salbutamol, terbutaline, rimiterol, fenoterol, reproterol, adrenaline, pirbuterol, isoprenaline, orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol, procaterol, broxaterol, picumeterol, mabuterol, ipratropium bromide, beclomethasone, fluticasone, budesonide, tipredane, dexamethasone, betamethasone, fluocinolone, triamcinolone acetonide, mometasone, and pharmacologically acceptable esters and salts thereof.

64. (Amended) A pharmaceutical aerosol formulation as claimed in claim 46, further comprising a substance selected from the group consisting of adjuvants, carriers, flavouring agents, buffers, antioxidants and chemical stabilisers.

77. (Amended) The method of claim 76, wherein the formulation comprises a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane (P134a), 1,1,1,2,3,3,3-heptafluoropropane (P227), and 1,1-difluoroethane (P152a).

80. (Amended) The method of claim 76, wherein the surfactant is selected from the group consisting of an alkyl glucoside and an alkyl maltoside.

81. (Amended) The method of claim 76, wherein the medicament is selected from the group consisting of a β2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid. --

Please add new claims 84-101.

-- 84. A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of a β2-adrenoreceptor agonist and a glucocorticosteriod.

85. A pharmaceutical aerosol formulation as claimed in claim 84, further comprising a physiologically effective amount of an anticholinergic bronchodilator.

86. A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.

87. A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.

88. A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

89. A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) salmeterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

90. The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of a β2-adrenoreceptor agonist and a glucocorticosteriod.

91. The method of claim 90, wherein the formulation further comprises a physiologically effective amount of an anticholinergic bronchodilator.

92. The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.

93. The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.

94. The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

95. The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) salmeterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

96. The pharmaceutical aerosol formulation as claimed in claim 46, wherein the surfactant is decyl glucoside.

97. The pharmaceutical aerosol formulation as claimed in claim 46, wherein the surfactant is dodecyl maltoside.

98. The pharmaceutical aerosol formulation as claimed in claim 56, wherein the surfactant is decyl glucoside.

Sub H1 Cont.

99. The pharmaceutical aerosol formulation as claimed in claim 56, wherein the surfactant is dodecyl maltoside.

100. The pharmaceutical aerosol formulation as claimed in claim 57, wherein the surfactant is decyl glucoside.

101. The pharmaceutical aerosol formulation as claimed in claim 57, wherein the surfactant is dodecyl maltoside.--